
Jimmy
PharmD
| Phenytoin | Valproic Acid | Levetiracetam | Lacosamide | ||
| Dose | Loading dose: 17 to 20 mg/kg IV (max dose 2 g) Maintenance dose: 100 mg every 8 hours or 5 mg/kg/day divided q8h (individual doses not to exceed 400 mg) Duration not to exceed 7 days | 10 – 15 mg/kg/day | Loading dose: 20 mg/kg IV infused over 5-20 min Maintenance dose: 1 g IV over 15 min every 12 hours for 7 days (may be increased to 1.5 g q12) | 50 – 100 mg IV twice daily May give loading dose of 200 mg | |
| Administration | IV piggyback rate of ≤50 mg/minute | IV piggyback over 60 minutes at a rate ≤20 mg/minute | IV push or piggyback over 5-20 min | Bolus: May be administered undiluted at ≤80 mg/minute Infusion: over 30 to 60 minutes | |
| PK/PD | Onset: 30 min – 1 hour Half-life:10 to 12 hours. | Peak: <1 hour Half-life:9 to 19 hours | Peak: 5-30 minutes Half-life: 6-8 hours | Peak: < 1 hour Half-life: ~13 hours | |
| Adverse Effects | Hematologic effects, cardiovascular effects, CNS effects, gingival hyperplasia, hepatotoxicity | CNS effects, hematologic effects, hepatotoxicity, encephalopathy, pancreatitis | CNS depression, hypersensitivity reactions, psychiatric and behavioral abnormalities, increased blood pressure, asthenia | Cardiac arrhythmias including bradycardia, AV block, CNS effects | |
| Warnings | Vesicant, acute toxicity | Not recommended for post-traumatic seizure prophylaxis in patients with acute head trauma | Caution in renal impairment. | Administer loading doses under medical supervision due to increased incidence of CNS adverse reactions | |
| Journal | Recommendations | |
| Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition – 2017 | Phenytoin is recommended to decrease the incidence of early PTS (within 7 d of injury), when the overall benefit is thought to outweigh the complications associated with treatment. There is insufficient evidence to recommend levetiracetam compared with phenytoin regarding efficacy in preventing early post-traumatic seizures and toxicity. | |
| Author, year | Design/ sample size | Intervention & Comparison | Outcome |
| Temkin, 1990 | A randomized, double-blind study N = 404 | Phenytoin vs Placebo | Within the first week 3.6% of phenytoin patients experienced seizure compared to 14.2% (p<0.001) Between day 8-1 year 21.5% of patients in phenytoin group experienced seizure compared to 15.7% in placebo group Phenytoin is effective in reducing seizures within the first 7 days after severe head injury |
| Young, 2004 | Randomized, Double-Blinded, Placebo- Controlled Trial in pediatric patients (age < 16 yo)
N = 102 |
Phenytoin vs Placebo for prevention of early posttraumatic seizures | During the 48-hour observation period, 3 of 46 (7%) patients in the phenytoin group and 3 of 56 (5%) patients in the placebo group experienced a posttraumatic seizure. No significant difference in survival or neurologic outcome between the two groups. Phenytoin did not significantly reduce the rate of posttraumatic seizures at 48 hours, neurologic outcomes, or overall survival at 30 days. |
| Jones, 2008 | Prospective, single-center trial N = 32 | Phenytoin vs Levetiracetam in patients with severe TBI (GCS 3-8) | Patients treated with levetiracetam and phenytoin had equivalent incidence of seizure activity (p = 0.556) Patients receiving levetiracetam had a higher incidence of abnormal EEG findings (p = 0.003). Levetiracetam is as effective as phenytoin in preventing early posttraumatic seizures but is associated with an increased seizure tendency on EEG |
| Temkin, 1990 | A randomized, double-blind study N = 404 | Phenytoin vs Placebo | Within the first week 3.6% of phenytoin patients experienced seizure compared to 14.2% (p<0.001) Between day 8-1 year 21.5% of patients in phenytoin group experienced seizure compared to 15.7% in placebo group Phenytoin is effective in reducing seizures within the first 7 days after severe head injury |
| Szaflarski, 2009 | Prospective, single-center, randomized, single-blinded comparative trial N = 52 | Levetiracetam vs Phenytoin in patients with severe traumatic brain injury (sTBI) or subarachnoid hemorrhage | Levetiracetam patients experienced better long-term outcomes than those on phenytoin. No differences between groups in seizure occurrence during cEEG (levetiracetam 5/34 vs. phenytoin 3/18; P = 1.0) or at 6 months (levetiracetam 1/20 vs. phenytoin 0/14; P = 1.0), or mortality (levetiracetam 14/34 vs. phenytoin 4/18; P = 0.227). Lower frequency of worsened neurological status (P = 0.024), and gastrointestinal problems (P = 0.043) in levetiracetam group Levetiracetam improved long-term outcomes of compared to phenytoin with less ADRs and may be an alternative. |
| Chi-yuan, 2010 | Retrospective, cohort study N = 171 | Sodium Valproate vs Placebo in early posttraumatic seizures in traumatic brain injury (TBI) patients. | No patients who received sodium valproate treatment experienced seizures; however, this was not statistically significant. Sodium valproate is effective in decreasing the risk of early posttraumatic seizures in severe TBI patients |
| Inaba, 2012 | Prospective, comparative study N = 1,191 | Levetiracetam vs Phenytoin for prevention of early post-traumatic seizures | No difference in seizure rate (1.5% vs.1.5%, p = 0.997) No difference between levetiracetam and phenytoin in the prevention of early post traumatic seizures, mortality or ADRs in patients following TBI. |
| Caballero, 2013 | Multicenter retrospective analysis N = 90 | Phenytoin vs Levetiracetam in TBI with at least one day of EEG monitoring | Prevalence of EEG-confirmed seizure activity was similar between the levetiracetam and phenytoin groups (28% vs 29%; p = .99). The median daily cost of levetiracetam therapy was $43 compared to $55 for phenytoin therapy and monitoring (p = .08). Levetiracetam may be an alternative treatment option for seizure prevention inTBI patients in the ICU while also providing lower costs for drug therapy and monitoring. |
| Kruer, 2013 | Retrospective observational study N = 109 | Phenytoin vs Levetiracetam in patients with a TBI and GCS < 8. | 79 out of 81 (98%) patients admitted between 2000 and 2007 received PHT, whereas 18 of 28 (64%) patients admitted between 2008 and 2010 received LEV. 1 patient out of 89 receiving phenytoin had a posttraumatic seizure and 1 patient out of 20 recieving levetiracetam experiences a posttraumatic seizure Only 2 patients experienced posttraumatic seizure after receiving AED, indicating low incidence of posttraumatic seizures. |
| Gabriel, 2014 | Single-center, prospective cohort analysis N = 19 | Phenytoin vs Levetiracetam after severe TBI | No difference in Glasgow Outcome Scale–Extended score assessed ≥6 months after injury No difference in early seizures (p = 0.53) or late seizures (p = 0.53) Higher days with fever experienced in the hospital in the phenytoin group. Long-term functional outcome in patients who experienced a TBI was not affected by treatment with PHT or LEV. |
| Khan, 2016 | Randomized controlled trial N = 154 | Phenytoin vs Levetiracetam in patients with moderate to severe head trauma | Phenytoin was effective in preventing early post traumatic seizures in 73 of 77 patients (94.8%) Levetiracetam effectively controlled seizures in 70 of 77 patients (90.95%) cases No statistically significant difference in the efficacy of Phenytoin and Levetiracetam in prophylaxis of early post-traumatic seizures in moderate to severe traumatic brain injury. |
Level Up Your Practice
Join thousands of pharmacy professionals learning with PACU.